BRPI0920246A2 - método de preparação de alfa-beta peptídios biologicamente ativos. - Google Patents

método de preparação de alfa-beta peptídios biologicamente ativos.

Info

Publication number
BRPI0920246A2
BRPI0920246A2 BRPI0920246A BRPI0920246A BRPI0920246A2 BR PI0920246 A2 BRPI0920246 A2 BR PI0920246A2 BR PI0920246 A BRPI0920246 A BR PI0920246A BR PI0920246 A BRPI0920246 A BR PI0920246A BR PI0920246 A2 BRPI0920246 A2 BR PI0920246A2
Authority
BR
Brazil
Prior art keywords
preparation
biologically active
active alpha
beta peptides
peptides
Prior art date
Application number
BRPI0920246A
Other languages
English (en)
Inventor
M Johnson Lisa
H Gellman Samuel
S Horne William
Original Assignee
Winconsin Alumni Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winconsin Alumni Res Foundation filed Critical Winconsin Alumni Res Foundation
Publication of BRPI0920246A2 publication Critical patent/BRPI0920246A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
BRPI0920246A 2008-10-17 2009-10-14 método de preparação de alfa-beta peptídios biologicamente ativos. BRPI0920246A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10620508P 2008-10-17 2008-10-17
US22932509P 2009-07-29 2009-07-29
US12/578,993 US8642536B2 (en) 2008-10-17 2009-10-14 Method of making biologically active alpha-beta peptides
PCT/US2009/060659 WO2010045342A1 (en) 2008-10-17 2009-10-14 Method of making biologically active alpha-beta peptides

Publications (1)

Publication Number Publication Date
BRPI0920246A2 true BRPI0920246A2 (pt) 2017-06-27

Family

ID=41572553

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920246A BRPI0920246A2 (pt) 2008-10-17 2009-10-14 método de preparação de alfa-beta peptídios biologicamente ativos.

Country Status (10)

Country Link
US (3) US8642536B2 (pt)
EP (1) EP2337788B1 (pt)
JP (2) JP6265583B2 (pt)
KR (1) KR20110071014A (pt)
CN (1) CN102245625A (pt)
AU (1) AU2009303389B2 (pt)
BR (1) BRPI0920246A2 (pt)
CA (1) CA2740873C (pt)
IL (1) IL212123A (pt)
WO (1) WO2010045342A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617011A1 (en) * 2010-09-14 2013-07-24 Ramot at Tel Aviv University, Ltd. Cell occupancy measurement
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
US10501518B2 (en) * 2013-06-23 2019-12-10 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (PTH) and method of using same
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
EP3466979B1 (en) * 2013-08-21 2019-11-06 UREKA Sarl Peptide-oligourea chimeric compounds and methods of their use
US20160272691A1 (en) * 2013-09-18 2016-09-22 Ndsu Research Foundation COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH y-HERPESVIRUSES
WO2015112700A1 (en) * 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
KR101551143B1 (ko) 2014-07-28 2015-09-08 성균관대학교산학협력단 생체적합성 단백질, 이를 포함하는 생체적합성 단백질 젤과 전도성 단백질 젤 및 그의 제조방법
EP3225993B1 (en) 2015-05-29 2019-12-25 Sysmex Corporation Method for measuring cholesterol uptake capacity of lipoproteins
US10414722B2 (en) 2015-06-22 2019-09-17 Ureka Sarl Bioinspired catalysis using oligourea helical foldamers
WO2017037142A1 (en) 2015-08-31 2017-03-09 Centre National De La Recherche Scientifique (Cnrs) Foldamer helix bundle-based molecular encapsulation
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
US10993459B2 (en) 2019-09-23 2021-05-04 Ralph Yoder Method for unlocking bioactive proteins
WO2023069728A1 (en) 2021-10-22 2023-04-27 Wisconsin Alumni Research Foundation Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587151T2 (de) 1984-12-20 1993-07-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
ATE95193T1 (de) 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
EP0296123B1 (en) 1987-06-19 1994-08-31 Sandoz Ag Cyclic peptolides
IT1219652B (it) 1987-06-23 1990-05-24 Sandoz Ag 8-acilamminoergolina,la sua preparazione e il suo impiego come medicamneto
GB2239178B (en) 1987-07-10 1991-11-27 Sandoz Ltd Somatostatin analogues for the treatment of breast cancer
GB2240476B (en) 1987-07-11 1992-03-18 Sandoz Ltd 5 ht-3 antagonists for the prevention or reduction of dependence
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
DK163689A (da) 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
HU214591B (hu) 1989-12-14 1998-04-28 Novartis Ag. Eljárás egy naftoxazinszármazék malonátsójának és az ilyen hatóanyagot tartalmazó gyógyszerkészítmények előállítására
DE4033496A1 (de) 1990-10-20 1992-04-23 Sandoz Ag Neue ergolinderivate, ihre herstellung und verwendung
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
DE4131584A1 (de) 1991-09-23 1993-03-25 Sandoz Ag Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika
DE4139143A1 (de) 1991-11-28 1993-06-03 Sandoz Ag Neue benzochinoxaline, ihre herstellung und verwendung
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994012493A1 (en) 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
GB9225396D0 (en) 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds
NZ262415A (en) 1993-03-03 1996-10-28 Sandoz Ltd Peptide boronic acid inhibitors having protease inhibiting activity
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
DE4329776A1 (de) 1993-09-03 1995-03-09 Sandoz Ag Naphthoxazine, ihre Herstellung und Verwendung
GB9322828D0 (en) 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
DE19612805A1 (de) * 1996-04-01 1997-10-02 Hoechst Ag Antifungische Peptide aus Scleroderma texense
AU3258197A (en) 1996-06-13 1998-01-07 Novartis Ag Peptides
US6060585A (en) 1997-03-04 2000-05-09 Wisconsin Alumni Research Foundation β-polypeptide foldamers of well-defined secondary structure
US20020037997A1 (en) 1997-03-04 2002-03-28 Gellman Samuel H. Beta-amino acids
ES2232196T3 (es) 1998-12-23 2005-05-16 The Horticulture And Food Research Institute Of New Zealand Limited Inhibidor de la serin proteasa.
US20070154882A1 (en) 2005-03-10 2007-07-05 Teresa Compton Beta-polypeptides that inhibit cytomegalovirus infection
EP1945691A2 (en) 2005-08-26 2008-07-23 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
US7820858B2 (en) 2006-03-25 2010-10-26 Wisconsin Alumni Research Foundation Concise β2-amino acid synthesis via organocatalytic aminomethylation
US9168329B2 (en) 2006-09-01 2015-10-27 Wisconsin Alumni Research Foundation Beta-peptides with antifungal activity
US9738697B2 (en) * 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1

Also Published As

Publication number Publication date
EP2337788A1 (en) 2011-06-29
CN102245625A (zh) 2011-11-16
JP6265583B2 (ja) 2018-01-24
AU2009303389A1 (en) 2010-04-22
WO2010045342A1 (en) 2010-04-22
CA2740873C (en) 2019-09-10
US20140315791A1 (en) 2014-10-23
IL212123A0 (en) 2011-06-30
US8642536B2 (en) 2014-02-04
KR20110071014A (ko) 2011-06-27
US20130177981A1 (en) 2013-07-11
US10647743B2 (en) 2020-05-12
IL212123A (en) 2017-04-30
CA2740873A1 (en) 2010-04-22
US20100099185A1 (en) 2010-04-22
EP2337788B1 (en) 2016-03-23
US9416156B2 (en) 2016-08-16
JP2015193648A (ja) 2015-11-05
JP2012505903A (ja) 2012-03-08
AU2009303389B2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
BRPI0920246A2 (pt) método de preparação de alfa-beta peptídios biologicamente ativos.
BRPI0822775A2 (pt) Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa.
HK1223946A1 (zh) 生物活性肽
BRPI1014975A2 (pt) sistema de entrega de implante
BRPI1014885A8 (pt) "azetidinil diamidas como inibidores de monoacilglicerol lipase."
IL215643A0 (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
BRPI0919090A2 (pt) prepraração de ácido acético.
BR112012003716A2 (pt) estruturas de implante porosas
BR112012006414A2 (pt) método de preparação de proteína derivados de plantas
BRPI0908439A2 (pt) sistema de implante mamário
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
IT1400544B1 (it) Procedimento di detossificazione di tessuto biologico.
BRPI1009447A2 (pt) métodos de purificação de proteínas imunofarmacêuticas modulares pequenas
SMT201500142B (it) Procedimento per la purificazione di proteine
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
IT1400545B1 (it) Procedimento per la preparazione di tessuto biologico per protesi biologiche.
DK2307543T3 (da) Forbedret proteinekspressionssystem
BRPI0921947A2 (pt) formulações de proteína terapêutica
BRPI1013975A2 (pt) método e sistema de implante endoscópico.
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
GB0817507D0 (en) Protein cages
BRPI1010121A2 (pt) método de tratamento biológico
BR112012014495A2 (pt) cosmético de autonivelamento.
BRPI0915899A2 (pt) sistema de implante aperfeiçoado
BR112013010541A2 (pt) método de preparação de 1,3,5-trioxano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]